Evaluating the Maintenance of Efficacy and Tolerability when Transitioning from IV anti-CD20 Therapy to Ublituximab: ENHANCE Study Design, Patient Demographics and Preliminary Data

site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
Drug Category: Array
Conference Category: Array
Lead Author: Foley J, et al.
Published Date: 11/10/2023
Download Link: /wp-content/uploads/2023/10/Foley-ENHANCE-Study-Design_ECTRIMS-2023_-Poster_Final.pdf
Download Text:
Popup Confirmation?:
astra-migrate-meta-layouts: set
Scroll to Top